Biogen cut its full-year profit forecast after booking acquisition-related charges, offsetting an otherwise positive first quarter. Earnings beat expectations on stronger-than-estimated sales of its Alzheimer's franchise and newer rare-disease treatments. The update is likely to influence the stock, but the article provides limited detail beyond the guidance reduction and earnings beat.
Biogen cut its full-year profit forecast after booking acquisition-related charges, offsetting an otherwise positive first quarter. Earnings beat expectations on stronger-than-estimated sales of its Alzheimer's franchise and newer rare-disease treatments. The update is likely to influence the stock, but the article provides limited detail beyond the guidance reduction and earnings beat.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
